Absci Corporation entered into an underwriting agreement on June 24, 2026, to issue and sell 13,495,277 shares of common stock at $7.41 per share. The company expects to net approximately $93.5 million to fund the advancement of its AI-designed anti-PRLR antibody product candidate, ABS-201, for androgenetic alopecia and endometriosis, and for general corporate purposes. Absci Corp is a biotechnology company focused on developing AI-designed antibody products.

Absci Corporation announced interim Phase 1 data from its HEADLINE™ trial of ABS-201 on June 24, 2026. The company released these clinical results via a press release incorporated as Exhibit 99.1. Absci Corporation is a biotechnology company focused on drug discovery.